Decatur-Morgan Hospital to install Safe Haven Baby Box, 16th box in Alabama
To celebrate this addition, the hospital will host an installation and opening event on March 31 at 1:30 p.m.
'Providing a Safe Haven Baby Box at Decatur Morgan Hospital is a critical step in ensuring that parents in crisis have a secure and anonymous option,' Kelli Powers, President of Decatur Morgan Hospital said. 'We are honored to be able to offer this resource, reinforcing our commitment to the well-being of our community.'
The Safe Haven Baby Box is designed as a safety mechanism that is installed in the exterior wall of the hospital. Once a baby is placed inside the box, the outside door will lock automatically to ensure security while hospital staff examine the baby from the inside.
Since 2016, Safe Haven Baby Boxes have provided a discreet and secure option for parents under the Safe Haven Law, which allows the legal surrender of infants at designated locations without fear of prosecution. The organization also operates a 24-hour hotline to provide assistance and guidance to parents in crisis.
In October 2024, the Athens-Limestone Hospital installed a Safe Haven Baby Box, which, according to officials, made it the seventh facility across the state to offer the baby boxes.
This addition at the Decatur-Morgan Hospital makes it the 16th box in Alabama and the 331st box in the nation.
For more information about Safe Haven Baby Boxes, you can visit its website here.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer
Veteran commercial leader to scale AI-enabled NAMkind™ liver and intestine toxicology services in a rapidly growing market SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the 'Company' or 'VivoSim Labs'), a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional ('3D') human tissue models of liver and intestine, announced today that it has appointed Tony Lialin as its Chief Commercial Officer. Mr. Lialin brings more than two decades of experience turning breakthrough life science platforms into scalable, predictable revenue. He has built commercial teams from the ground up, forged strategic pharma partnerships, and helped scale multiple businesses that were later acquired by leading industry players. At VivoSim Labs, he will lead go-to-market strategy, partnerships, and the expansion of the Company's San Diego-based services that combine organ-specific 3D models with AI-driven analytics to deliver decision-ready insights earlier in development. Market Opportunity: According to an internal analysis conducted by VivoSim Labs in July 2025, the global combined liver and gastrointestinal in-vitro models and toxicology services market generated $641M in revenue in 2024. Services represented 53.1% of revenue vs. models at 46.9% of revenue. The United States accounted for $325M (50.8%) of the global market for liver toxicology models and services. Adoption of 3D human-relevant systems is rising, with the global in vitro liver model market growing at 5.9% CAGR from 2020 to 2024. Category Tailwinds: Biopharma sponsors are accelerating the use of non-animal new approach methodologies (NAMs). Regulatory momentum, including the FDA Modernization Act 2.0 (2022), supports validated alternatives and is catalyzing broader adoption of human-relevant in vitro models for ADME and toxicology. How AI Helps: VivoSim Labs applies AI to quantify multi-parametric toxicity signatures across liver and intestinal organoid assays. By improving signal-to-noise in dose-response analyses, the platform helps project teams prioritize candidates and plan studies with greater confidence. 'VivoSim Labs sits at the intersection of biology and AI. Our NAMkind™ models are designed to answer make-or-break questions earlier,' said Tony Lialin, Chief Commercial Officer, VivoSim Labs. 'We will scale a high-touch, consultative service from our San Diego lab so pharma and biopharma teams get decision-ready toxicology insights that aim to streamline pre-IND decision-making and reduce late-stage surprises.' 'Tony has a rare track record of turning disruptive science into durable commercial engines,' said Keith Murphy, Executive Chairman, VivoSim Labs. 'As sponsors move rapidly to 3D, human-relevant models, they want a partner—not just a plate or a protocol—to guide critical decisions. Tony knows how to build the solutions that our customers need.' About VivoSim Labs VivoSim Labs, Inc. ("VivoSim" and the 'Company'), is a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional ('3D') human tissue models of liver and intestine. The Company offers partners liver and intestinal toxicology insights using its new approach methodologies ("NAM") models. The Company anticipates accelerated adoption of human tissue models following the U.S. Food and Drug Administration ('FDA") announcement on April 10, 2025 to refine animal testing requirements in favor of these non-animal NAM methods. VivoSim Labs operates from San Diego, CA. Visit Forward-Looking Statements Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Forward-looking statements include statements regarding expansion of the Company's San Diego-based services; the potential for the Company's organ-specific 3D models and AI-driven analytics to deliver decision-ready insights earlier in development; the market opportunity and market size of gastrointestinal in-vitro models and toxicology services; and the ability of the Company's services to improve signal-to-noise in dose-response calls or help project teams prioritize candidates and studies with greater confidence. Such forward-looking statements are not guarantees of performance and actual actions or events could differ materially from those contained in such statements. These risks and uncertainties and other factors are identified and described in more detail in the Company's filings with the SEC, including its Annual Report on Form 10-K filed with the SEC on June 5, 2025, as such risk factors are updated in its most recently filed Quarterly Report on Form 10-Q filed with the SEC on August 12, 2025. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that the Company may issue in the future. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events, or circumstances or to reflect the occurrence of unanticipated events. ContactInvestor Relationsinfo@ Labs, in to access your portfolio
Business Wire
3 hours ago
- Business Wire
RAM Technologies' Rapid Growth Earns National Recognition on Inc. 5000 List
PHILADELPHIA--(BUSINESS WIRE)--RAM Technologies, Inc., a leading technology enabled services provider to Medicare Advantage, Special Needs and Managed Medicaid health plans, has earned a place on the 2025 Inc. 5000 list, the most prestigious ranking of the fastest-growing private companies in America. With three-year revenue growth of nearly 100%, this marks the company's ninth time on the list. Our growth is the result of a clear mission to equip government-sponsored health plans with software and services to operate efficiently and put members at the center of every decision. Share The Inc. 5000 offers a data-driven look at the nation's most successful companies within the economy's most dynamic segment—independent, entrepreneurial businesses. Rankings are based on percentage revenue growth from 2021 to 2024, and RAM Technologies was honored for its exceptional growth and innovation. 'It's an honor to once again be recognized on the Inc. 5000 list,' said Robert Tulio, CEO of RAM Technologies. 'Our growth is the result of a clear mission to equip government-sponsored health plans with software and services to operate efficiently and put members at the center of every decision. This achievement reflects the impact we're making in the healthcare industry, and our team's focus on innovation and quality.' The company's sustained growth has been fueled by expanding relationships with health plans nationwide, a commitment to exceptional client service and the ability to provide BPaaS solutions that enhance outcomes for clients. RAM Technologies specializes in delivering purpose-built solutions for government-sponsored health plans. The company's core platform, HEALTHsuite Advantage, gives health plans added flexibility through the choice of SaaS and BPaaS deployment models. By combining software with expert implementation and support, RAM helps health plans reduce costs, streamline operations and improve member experiences. 'Our solutions give health plans tools to operate more efficiently, deliver a better experience for members and ensure compliance with regulatory requirements,' said Tulio. 'We're proud to have achieved sustained growth in such a competitive market, and we remain focused on delivering solutions to help our clients succeed.' For the full list, company profiles, and a searchable database by industry and location, visit: About RAM Technologies RAM Technologies is a leading provider of enterprise solutions for government-sponsored healthcare payers. For over 44 years RAM Technologies has led the way in the creation of comprehensive, end-to-end SaaS and BPaaS solutions for health plans administering Medicare Advantage, Managed Medicaid and Special Needs plans. Our deep understanding of Medicare and Medicaid guarantees seamless integration and operational ease, allowing health plan staff to focus on what matters most. To learn more about RAM Technologies visit
Yahoo
5 hours ago
- Yahoo
Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 20
ESTERO, FL / / August 14, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending drug and supplement delivery technology, today announced that Kraig Higginson, Interim Chief Executive Officer of Aspire, will be presenting at the upcoming Sidoti Virtual Investor Conference on August 20 at 1:45 PM Eastern. Investors and other interested individuals may access the virtual presentation here: One-on-One Meetings Aspire will also host virtual one-on-ones with investors on Wednesday, August 20 and Thursday, August 21, 2025. To register for the presentation or one-on ones, visit A replay of the presentation will be available on the investor relations section of Aspire's website at About Aspire Biopharma, Inc. Aspire Biopharma has developed a patent-pending disruptive technology that can deliver supplements and drugs to the body rapidly and precisely with less negative impact to the system by going directly to the bloodstream and avoiding the gastrointestinal tract. For more information, please visit Aspire Biopharma Holdings, Inc. ContactPCG AdvisoryKevin McGrath+1-646-418-7002kevin@ SOURCE: Aspire Biopharma Holdings, Inc. View the original press release on ACCESS Newswire
